COAG Stock: Price, Earnings History and SEC Filings
Hemab Therapeutics Holdings, Inc. (COAG) last traded at $41.45, up 2.55% on the latest session and up 34.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.80 against an analyst estimate of $-0.63, a miss of 27.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
COAG earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.80 | $-0.63 | -26.98% |
COAG beat the analyst EPS estimate in 0 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for COAG
- 8-K · Sep 24, 2026Officer or director change
- 10-Q · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 21, 2026
- 8-K · May 21, 2026Results of operations, Financial statements and exhibits
- 8-K · May 11, 2026Officer or director change
- 8-K · May 4, 2026Bylaw change, Other events, Financial statements and exhibits
- 424B4 · May 1, 2026
- S-1 · Apr 10, 2026
Insider filing activity
COAG insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
COAG news
No recent headlines found. The live terminal has the full news feed.
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. (COAG) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.